Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Antihypertensive drug prescribing and persistence among new elderly users: Implications for persistence improvement interventions

  • Karen Tu*
  • , Laura N. Anderson
  • , Debra A. Butt
  • , Hude Quan
  • , Brenda R. Hemmelgarn
  • , Norm R. Campbell
  • , Finlay A. McAlister
  • , Oliver Baclic
  • , Gillian Bartlett
  • , Guanmin Chen
  • , Sulan Dai
  • , Michael Hill
  • , Helen Johansen
  • , Nadia Khan
  • , Lisa Lix
  • , Jay Onysko
  • , Mark Smith
  • , Larry Svenson
  • , Gary Teare
  • , Robin Walker
  • Andy Wielgosz
*Autor correspondiente de este trabajo
  • Institute for Clinical Evaluative Sciences
  • University of Toronto
  • Toronto Western Hospital University of Toronto
  • University of Calgary
  • University of Alberta

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

23 Citas (Scopus)

Resumen

Background: The objective of this study was to examine persistence rates and factors influencing persistence for new elderly users of antihypertensive drugs. Methods: We conducted a population-based cohort study in Ontario of adults aged 66 years or older to identify new users of antihypertensive medications between 1999 and 2010. Two-year therapy and class persistence were defined as persistence on any antihypertensive medication and persistence only on the same antihypertensive medication class, respectively. Results: From 1999-2010, the prevalence of antihypertensive drug use increased from 47.8%-60.5% (P < 0.0001). Persistence was evaluated in 420,148 new users of antihypertensive drugs. After 2 years, therapy persistence was 58.9% and varied according to initial class prescribed, from 52.3% for diuretics to 64.1% for angiotensin-converting enzyme inhibitors. Class persistence ranged from 25.3% for diuretics to 35.8% for angiotensin II receptor blockers. Therapy persistence rates were greater in new users from more recent years (adjusted odds ratio [aOR], 1.24; 95% confidence interval [CI], 1.21-1.27). Subgroups that demonstrated poorer persistence included patients older than 75 years (aOR, 0.95; 95% CI, 0.94-0.96), those with lowest neighbourhood income quintile (aOR, 0.81; 95% CI, 0.80-0.83 compared with the highest quintile), those from urban vs rural areas (aOR, 0.83; 95% CI, 0.81-0.84), and those who started on diuretics as initial monotherapy compared with all other drug classes. Conclusions: Although 2-year therapy and class persistence were low for new users of antihypertensive drugs, improvements have occurred over the past decade. Our data highlight subgroups to target for future persistence improvement interventions.

Idioma originalInglés
Páginas (desde-hasta)647-652
Número de páginas6
PublicaciónCanadian Journal of Cardiology
Volumen30
N.º6
DOI
EstadoPublicada - 1 jun 2014

Huella

Profundice en los temas de investigación de 'Antihypertensive drug prescribing and persistence among new elderly users: Implications for persistence improvement interventions'. En conjunto forman una huella única.

Citar esto